ritonavir	amprenavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	0	D019438	C095108
ritonavir	amprenavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	0	D019438	C095108
ritonavir	amprenavir	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	0	D019438	C095108
ritonavir	amprenavir	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	0	D019438	C095108
ritonavir	darunavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	460132	D019438	460132
ritonavir	darunavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	460132	D019438	460132
ritonavir	darunavir	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	460132	D019438	460132
ritonavir	darunavir	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	460132	D019438	460132
ritonavir	NORVIR	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	0	D019438	196479
ritonavir	NORVIR	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	0	D019438	196479
ritonavir	NORVIR	2	2	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	0	D019438	196479
ritonavir	NORVIR	2	2	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	0	D019438	196479
ritonavir	NORVIR	2	4	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated.  		85762	0	D019438	196479
ritonavir	NORVIR	2	4	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated.  		85762	0	D019438	196479
ritonavir	NORVIR	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	0	D019438	196479
ritonavir	NORVIR	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	0	D019438	196479
ritonavir	NORVIR	3	2	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	0	D019438	196479
ritonavir	NORVIR	3	2	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	0	D019438	196479
ritonavir	NORVIR	3	4	true	positive	Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated.  		85762	0	D019438	196479
ritonavir	NORVIR	3	4	true	positive	Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated.  		85762	0	D019438	196479
ritonavir	NORVIR	6	4	true	positive	Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated.  Co-administration with other CYP3A substrates may require a dose adjustment or additional monitoring as shown in Table 5.  Ritonavir also inhibits CYP2D6 to a lesser extent.  		85762	0	D019438	196479
ritonavir	NORVIR	6	4	true	positive	Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated.  Co-administration with other CYP3A substrates may require a dose adjustment or additional monitoring as shown in Table 5.  Ritonavir also inhibits CYP2D6 to a lesser extent.  		85762	0	D019438	196479
ritonavir	saquinavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	83395	D019438	D019258
ritonavir	saquinavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	83395	D019438	D019258
ritonavir	saquinavir	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	83395	D019438	D019258
ritonavir	saquinavir	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	83395	D019438	D019258
ritonavir	tipranavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	190548	D019438	C107201
ritonavir	tipranavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	190548	D019438	C107201
ritonavir	tipranavir	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	190548	D019438	C107201
ritonavir	tipranavir	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	190548	D019438	C107201
ritonavir	fosamprenavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	358262	D019438	358262
ritonavir	fosamprenavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	358262	D019438	358262
ritonavir	fosamprenavir	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	358262	D019438	358262
ritonavir	fosamprenavir	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	358262	D019438	358262
ritonavir	atazanavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	343047	D019438	343047
ritonavir	atazanavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	343047	D019438	343047
ritonavir	atazanavir	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	343047	D019438	343047
ritonavir	atazanavir	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	343047	D019438	343047
ritonavir	p450	2	2	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	none	D019438	none
ritonavir	p450	2	2	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	none	D019438	none
ritonavir	p450	3	2	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	none	D019438	none
ritonavir	p450	3	2	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	none	D019438	none
amprenavir	darunavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		0	460132	C095108	460132
amprenavir	darunavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		0	460132	C095108	460132
amprenavir	NORVIR	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		C095108	196479
amprenavir	NORVIR	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		C095108	196479
amprenavir	Ritonavir	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		0	85762	C095108	D019438
amprenavir	Ritonavir	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		0	85762	C095108	D019438
amprenavir	Ritonavir	1	3	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		0	85762	C095108	D019438
amprenavir	Ritonavir	1	3	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		0	85762	C095108	D019438
amprenavir	saquinavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		0	83395	C095108	D019258
amprenavir	saquinavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		0	83395	C095108	D019258
amprenavir	tipranavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		0	190548	C095108	C107201
amprenavir	tipranavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		0	190548	C095108	C107201
amprenavir	fosamprenavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		0	358262	C095108	358262
amprenavir	fosamprenavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		0	358262	C095108	358262
amprenavir	atazanavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		0	343047	C095108	343047
amprenavir	atazanavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		0	343047	C095108	343047
amprenavir	p450	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		0	none	C095108	none
amprenavir	p450	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		0	none	C095108	none
darunavir	NORVIR	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		460132	0	460132	196479
darunavir	NORVIR	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		460132	0	460132	196479
darunavir	NORVIR	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		460132	0	460132	196479
darunavir	NORVIR	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		460132	0	460132	196479
darunavir	Ritonavir	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		460132	85762	460132	D019438
darunavir	Ritonavir	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		460132	85762	460132	D019438
darunavir	Ritonavir	1	3	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		460132	85762	460132	D019438
darunavir	Ritonavir	1	3	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		460132	85762	460132	D019438
darunavir	saquinavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		460132	83395	460132	D019258
darunavir	saquinavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		460132	83395	460132	D019258
darunavir	tipranavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		460132	190548	460132	C107201
darunavir	tipranavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		460132	190548	460132	C107201
darunavir	fosamprenavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		460132	358262	460132	358262
darunavir	fosamprenavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		460132	358262	460132	358262
darunavir	atazanavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		460132	343047	460132	343047
darunavir	atazanavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		460132	343047	460132	343047
darunavir	p450	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		460132	none	460132	none
darunavir	p450	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		460132	none	460132	none
NORVIR	Ritonavir	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		0	85762	196479	D019438
NORVIR	Ritonavir	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		0	85762	196479	D019438
NORVIR	Ritonavir	1	3	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		0	85762	196479	D019438
NORVIR	Ritonavir	1	3	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		0	85762	196479	D019438
NORVIR	Ritonavir	2	2	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		0	85762	196479	D019438
NORVIR	Ritonavir	2	2	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		0	85762	196479	D019438
NORVIR	Ritonavir	2	3	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		0	85762	196479	D019438
NORVIR	Ritonavir	2	3	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		0	85762	196479	D019438
NORVIR	Ritonavir	4	2	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated.  		0	85762	196479	D019438
NORVIR	Ritonavir	4	2	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated.  		0	85762	196479	D019438
NORVIR	Ritonavir	4	3	true	positive	Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated.  		0	85762	196479	D019438
NORVIR	Ritonavir	4	3	true	positive	Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated.  		0	85762	196479	D019438
NORVIR	Ritonavir	4	6	true	positive	Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated.  Co-administration with other CYP3A substrates may require a dose adjustment or additional monitoring as shown in Table 5.  Ritonavir also inhibits CYP2D6 to a lesser extent.  		0	85762	196479	D019438
NORVIR	Ritonavir	4	6	true	positive	Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated.  Co-administration with other CYP3A substrates may require a dose adjustment or additional monitoring as shown in Table 5.  Ritonavir also inhibits CYP2D6 to a lesser extent.  		0	85762	196479	D019438
NORVIR	saquinavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		0	83395	196479	D019258
NORVIR	saquinavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		0	83395	196479	D019258
NORVIR	saquinavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		0	83395	196479	D019258
NORVIR	saquinavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		0	83395	196479	D019258
NORVIR	tipranavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		0	190548	196479	C107201
NORVIR	tipranavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		0	190548	196479	C107201
NORVIR	tipranavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		0	190548	196479	C107201
NORVIR	tipranavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		0	190548	196479	C107201
NORVIR	fosamprenavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		0	358262	196479	358262
NORVIR	fosamprenavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		0	358262	196479	358262
NORVIR	fosamprenavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		0	358262	196479	358262
NORVIR	fosamprenavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		0	358262	196479	358262
NORVIR	atazanavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		0	343047	196479	343047
NORVIR	atazanavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		0	343047	196479	343047
NORVIR	atazanavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		0	343047	196479	343047
NORVIR	atazanavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		0	343047	196479	343047
NORVIR	p450	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		0	none	196479	none
NORVIR	p450	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		0	none	196479	none
NORVIR	p450	2	2	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		0	none	196479	none
NORVIR	p450	2	2	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		0	none	196479	none
NORVIR	p450	4	2	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated.  		0	none	196479	none
NORVIR	p450	4	2	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated.  		0	none	196479	none
Ritonavir	saquinavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	83395	D019438	D019258
Ritonavir	saquinavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	83395	D019438	D019258
Ritonavir	saquinavir	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	83395	D019438	D019258
Ritonavir	saquinavir	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	83395	D019438	D019258
Ritonavir	tipranavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	190548	D019438	C107201
Ritonavir	tipranavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	190548	D019438	C107201
Ritonavir	tipranavir	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	190548	D019438	C107201
Ritonavir	tipranavir	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	190548	D019438	C107201
Ritonavir	fosamprenavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	358262	D019438	358262
Ritonavir	fosamprenavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	358262	D019438	358262
Ritonavir	fosamprenavir	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	358262	D019438	358262
Ritonavir	fosamprenavir	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	358262	D019438	358262
Ritonavir	atazanavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	343047	D019438	343047
Ritonavir	atazanavir	2	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	343047	D019438	343047
Ritonavir	atazanavir	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	343047	D019438	343047
Ritonavir	atazanavir	3	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	343047	D019438	343047
Ritonavir	p450	2	2	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	none	D019438	none
Ritonavir	p450	2	2	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		85762	none	D019438	none
Ritonavir	p450	3	2	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	none	D019438	none
Ritonavir	p450	3	2	false	none	7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co- administered with ritonavir.  		85762	none	D019438	none
saquinavir	tipranavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		83395	190548	D019258	C107201
saquinavir	tipranavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		83395	190548	D019258	C107201
saquinavir	fosamprenavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		83395	358262	D019258	358262
saquinavir	fosamprenavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		83395	358262	D019258	358262
saquinavir	atazanavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		83395	343047	D019258	343047
saquinavir	atazanavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		83395	343047	D019258	343047
saquinavir	p450	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		83395	none	D019258	none
saquinavir	p450	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		83395	none	D019258	none
tipranavir	fosamprenavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		190548	358262	C107201	358262
tipranavir	fosamprenavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		190548	358262	C107201	358262
tipranavir	atazanavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		190548	343047	C107201	343047
tipranavir	atazanavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		190548	343047	C107201	343047
tipranavir	p450	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		190548	none	C107201	none
tipranavir	p450	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		190548	none	C107201	none
fosamprenavir	atazanavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		358262	343047	358262	343047
fosamprenavir	atazanavir	1	1	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  		358262	343047	358262	343047
fosamprenavir	p450	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		358262	none	358262	none
fosamprenavir	p450	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		358262	none	358262	none
atazanavir	p450	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		343047	none	343047	none
atazanavir	p450	1	2	false	none	7 DRUG INTERACTIONS    See also Contraindications (4),Clinical Pharmacology (12.3)]    When co-administering NORVIR with other protease inhibitors (amprenavir, atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions.  7.1 Potential for NORVIR to Affect Other Drugs    Ritonavir has been found to be an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.  		343047	none	343047	none
